(VIANEWS) – VASTNED BELGIUM (VASTB.BR), SANOFI (SAN.PA), RETAIL ESTATES (RET.BR) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio so far. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. VASTNED BELGIUM (VASTB.BR)
78.85% Payout Ratio
Vastned Belgium is a public regulated real estate company (RREC), the shares of which are listed on Euronext Brussels (VASTB). Vastned Belgium invests exclusively in Belgian commercial real estate, more specifically in multi-functional retail properties located in the popular shopping cities of Antwerp, Brussels, Ghent and Bruges. The real estate portfolio also comprises high-end retail parks and retail warehouses. A smaller part of the portfolio is invested in hospitality and residential units.
Earnings Per Share
As for profitability, VASTNED BELGIUM has a trailing twelve months EPS of €2.79.
PE Ratio
VASTNED BELGIUM has a trailing twelve months price to earnings ratio of 10.86. Meaning, the purchaser of the share is investing €10.86 for every euro of annual earnings.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VASTNED BELGIUM’s EBITDA is 61.86.
More news about VASTNED BELGIUM.
2. SANOFI (SAN.PA)
50.08% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.65.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 15.09. Meaning, the purchaser of the share is investing €15.09 for every euro of annual earnings.
Sales Growth
SANOFI’s sales growth for the current quarter is 1.9%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 5.2% and a negative 5.6%, respectively.
More news about SANOFI.
3. RETAIL ESTATES (RET.BR)
31.81% Payout Ratio
The Belgian public real estate investment trust Retail Estates nv is a niche player specialised in making in out-of-town retail properties located on the periphery of residential areas or along main access roads to urban centres available to users. Real Estates NV acquires these real properties from third parties or builds and commercialises retail buildings for its own account. The buildings have useful areas ranging between 500m² and 3,000m². A typical retail building has an average area of 1,000 m². As of 31 December 2022, Retail Estates nv has 1,012 properties in its portfolio with a total retail area of 1,207,542 m², spread over Belgium and the Netherlands. The occupancy rate of the portfolio was 97.92% on 31 December 2022, compared to 97.83% on 31 March 2022. The fair value of the consolidated real estate portfolio of Retail Estates NV on 31 December 2022 is estimated at € 1,855 million by independent real estate experts. Retail Estates NV is listed on Euronext Brussels and Euronext Amsterdam and is registered as a public regulated real estate company.
Earnings Per Share
As for profitability, RETAIL ESTATES has a trailing twelve months EPS of €14.46.
PE Ratio
RETAIL ESTATES has a trailing twelve months price to earnings ratio of 4.54. Meaning, the purchaser of the share is investing €4.54 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.3%.
More news about RETAIL ESTATES.
4. HEINEKEN HOLDING (HEIO.AS)
31.33% Payout Ratio
Heineken Holding N.V., through its subsidiaries, engages in brewing and selling beer and cider in the Netherlands and internationally. The company's portfolio consists of approximately 300 international, regional, local, and specialty beers and ciders. The company was founded in 1864 and is based in Amsterdam, the Netherlands. Heineken Holding N.V. is a subsidiary of L'Arche Green N.V.
Earnings Per Share
As for profitability, HEINEKEN HOLDING has a trailing twelve months EPS of €4.66.
PE Ratio
HEINEKEN HOLDING has a trailing twelve months price to earnings ratio of 18.62. Meaning, the purchaser of the share is investing €18.62 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.6%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 24, 2023, the estimated forward annual dividend rate is 1.73 and the estimated forward annual dividend yield is 2.11%.
Volume
Today’s last reported volume for HEINEKEN HOLDING is 15853 which is 90.97% below its average volume of 175703.
Moving Average
HEINEKEN HOLDING’s value is way above its 50-day moving average of €75.38 and way above its 200-day moving average of €72.78.
Revenue Growth
Year-on-year quarterly revenue growth grew by 27.7%, now sitting on 28.72B for the twelve trailing months.
More news about HEINEKEN HOLDING.
